Notch ligand Delta-like 1 as a novel molecular target in childhood neuroblastoma

BMC Cancer
Paola BettinsoliMaurizio Memo

Abstract

Neuroblastoma is the most common extracranial solid malignancy in childhood, responsible for 15% of all pediatric cancer deaths. It is an heterogeneous disease that does not always respond to classical therapy; so the identification of new and specific molecular targets to improve existing therapy is needed. We have previously demonstrated the involvement of the Notch pathway in the onset and progression of neuroblastoma. In this study we further investigated the role of Notch signaling and identified Delta-like 1 (DLL1) as a novel molecular target in neuroblastoma cells with a high degree of MYCN amplification, which is a major oncogenic driver in neuroblastoma. The possibility to act on DLL1 expression levels by using microRNAs (miRNAs) was assessed. DLL1 mRNA and protein expression levels were measured in three different neuroblastoma cell lines using quantitative real-time PCR and Western Blot analysis, respectively. Activation of the Notch pathway as a result of increased levels of DLL1 was analyzed by Immunofluorescence and Western Blot methods. In silico tools revealed the possibility to act on DLL1 expression levels with miRNAs, in particular with the miRNA-34 family. Neuroblastoma cells were transfected with miRNA-34 f...Continue Reading

References

Jul 26, 2003·Cancer Letters·C Patrick ReynoldsBarry J Maurer
Oct 23, 2003·Nature Reviews. Cancer·Freddy Radtke, Kenneth Raj
Feb 10, 2004·Laboratory Investigation; a Journal of Technical Methods and Pathology·Anders EdsjöSven Påhlman
Jun 25, 2005·Current Cancer Drug Targets·Andrea Pession, Roberto Tonelli
Aug 2, 2005·Seminars in Cell & Developmental Biology·Robert A Cornell, Judith S Eisen
Nov 18, 2005·Blood·Kevin G Leong, Aly Karsan
Feb 21, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Lucio Miele
Mar 3, 2006·Cancer Research·Xao X TangNaohiko Ikegaki
May 16, 2006·Trends in Cell Biology·Aasia O Rehman, Cun-Yu Wang
Jun 2, 2007·Molecular Cell·Tsung-Cheng ChangJoshua T Mendell
Jun 26, 2007·Lancet·John M MarisSusan L Cohn
Oct 5, 2007·Journal of Cellular Biochemistry·Jennifer M BaileyMichael A Hollingsworth
Oct 9, 2007·Molecular and Cellular Neurosciences·Konstantina TsarovinaHermann Rohrer
Nov 3, 2007·Surgical Oncology·Titilope A Ishola, Dai H Chung
May 17, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Pingyu ZhangDennis P M Hughes
Aug 23, 2008·Cell Cycle·Dmitri LodyginHeiko Hermeking
Sep 27, 2008·Pediatric Blood & Cancer·Alberto Garaventa, Giorgio Perilongo
Nov 22, 2008·Cancer Letters·Zhiwei WangFazlul H Sarkar
Dec 20, 2008·Journal of Neurochemistry·Justin D LathiaAiwu Cheng
Mar 12, 2009·Journal of Cellular Biochemistry·Lars M Wagner, Mary K Danks
May 23, 2009·Cell Death and Differentiation·H Hermeking
Oct 22, 2009·British Journal of Cancer·A M JubbA L Harris
Feb 11, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·David C CorneyAlexander Yu Nikitin
Mar 11, 2010·Liver International : Official Journal of the International Association for the Study of the Liver·Feng YuJinjun Li
Mar 17, 2010·Cancer Treatment Reviews·Shakeel Modak, Nai-Kong V Cheung
Jun 19, 2010·The New England Journal of Medicine·John M Maris
Jun 24, 2010·Cancer Research·Jason F WigginsAndreas G Bader
Aug 19, 2010·Neuro-oncology·Giulia Ferrari-ToninelliMaurizio Memo
Jul 12, 2011·Cancer Biology & Therapy·Wen-Bo LiXiao-Rong Li
Nov 25, 2011·Breast Cancer Research : BCR·Yee-Ming LeeHuei-Wen Chen
Jan 18, 2012·Seminars in Pediatric Surgery·Andrew M Davidoff
Feb 22, 2012·Upsala Journal of Medical Sciences·Gianpiero Di LevaCarlo M Croce
Jul 12, 2012·Frontiers in Genetics·Andreas G Bader
Sep 1, 2012·Molecular Cancer Research : MCR·Jochen Buechner, Christer Einvik
Oct 30, 2012·Molecular Oncology·Martin D Jansson, Anders H Lund
Nov 7, 2012·Surgery Today·Isamu Hoshino, Hisahiro Matsubara
Nov 14, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Shahana MajidRajvir Dahiya
Dec 6, 2012·Clinical Pharmacology and Therapeutics·S P Nana-Sinkam, C M Croce
Jan 19, 2013·BMC Cancer·Ronald Tk PangWilliam Sb Yeung
Mar 6, 2013·Pharmacology & Therapeutics·Ingrid Espinoza, Lucio Miele

❮ Previous
Next ❯

Citations

Jun 23, 2018·Oncotarget·Paola BettinsoliMaurizio Memo
Sep 10, 2020·Journal of Gastrointestinal Cancer·Faranak Khanipouyani, Hassan Akrami
May 23, 2020·OncoTargets and Therapy·Meng-Xi XiuBo-Hai Kuang
May 13, 2020·Genome Biology·Mayilaadumveettil NishanaJane A Skok
Sep 12, 2020·Molecular Pharmacology·Lobna Faiz GharaibehWalhan Alshaer
Dec 10, 2020·Nature Reviews. Drug Discovery·Samarpan MajumderLucio Miele
Mar 16, 2021·Frontiers in Oncology·Omidvar RezaeiSoudeh Ghafouri-Fard
May 8, 2021·Cancer Metastasis Reviews·Sijing LiLi Sun

❮ Previous
Next ❯

Methods Mentioned

BETA
xenograft
transfection
PCR
scraping
confocal microscopy
flow cytometry

Software Mentioned

Graph Pad Prism
Zeiss
Target Scan
LSM5
Quantity One

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.